Search results for "DISEASE PROGRESSION"

showing 10 items of 835 documents

Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?

2017

Crohn's disease (CD) is a chronic inflammatory condition of the bowel, characterized by an alternation of remission and relapse phases, leading to a progressive intestinal damage with loss of function. Magnetic resonance enterography has been widely used in the past for the evaluation of fistulizing disease, but its use increased over time, being considered helpful in different moments of disease course. Intravenous injection of Gadolinium-based contrast agents has been demonstrated to be crucial to assess mucosal inflammation, transmural involvement, and extraintestinal disease. Recently, Gadolinium accumulation in human tissues has been increasingly reported, although clinical implication…

medicine.medical_specialtyPathologyMetabolic Clearance RateGadoliniumchemistry.chemical_elementContrast MediaGadoliniumDiseaseGastroenterology030218 nuclear medicine & medical imaging03 medical and health sciencesGadolinium storage condition0302 clinical medicineCrohn DiseaseInternal medicineMedicineHumansIn patientTissue DistributionContrast-enhanced Magnetic Resonance ImagingCrohn's diseasemedicine.diagnostic_testHepatologybusiness.industryCrohn's disease; Gadolinium; Gadolinium storage condition; Magnetic resonance imaging; Hepatology; GastroenterologyGastroenterologyMagnetic resonance imagingHepatologymedicine.diseaseMagnetic resonance enterographyMagnetic Resonance ImagingCrohn's diseasechemistryDisease Progression030211 gastroenterology & hepatologybusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Long-Term Evaluation of a Rat Model of Chronic Cholangitis Resembling Human Primary Sclerosing Cholangitis

2003

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder with a presumed autoimmune aetiopathogenesis. We have recently described a novel organ-specific rat model of fibrosing cholangitis induced by intrabiliary administration of the hapten-reagent 2,4,6-trinitrobenzenesulfonic acid (TNBS) with similarities to human PSC. In the present report, we have evaluated the long-term outcome of TNBS-induced cholangitis in this model. Mild stenosis of the common bile duct of female Lewis rats (n = 18) was achieved by subtotal ligation and cholangitis induced by TNBS injection (50 mg/kg) into the dilated bile duct after a second laparotomy. After 8 and 12 months, we found no evidence of …

medicine.medical_specialtyPathologyNecrosisCholangitis SclerosingImmunologyInflammationdigestive systemGastroenterologyAntibodies Antineutrophil CytoplasmicPrimary sclerosing cholangitisCholangiographyInternal medicinemedicineAnimalsHumansChronic CholangitisAnti-neutrophil cytoplasmic antibodymedicine.diagnostic_testCommon bile ductbusiness.industryAlanine TransaminaseGeneral Medicinemedicine.diseaseRatsDisease Models AnimalC-Reactive Proteinmedicine.anatomical_structureLiverTrinitrobenzenesulfonic AcidRats Inbred LewChronic DiseaseDisease ProgressionFemalemedicine.symptomLigationbusinessScandinavian Journal of Immunology
researchProduct

The influence of the C1-inhibitor BERINERT® and the protein-free haemodialysate ACTIHAEMYL20%® on the evolution of the depth of scald burns in a porc…

1997

Standardized deep partial-thickness burns were inflicted on domestic pigs by scalding 30 per cent of the skin surface for 25 s with 75 degrees C hot water. The animals (n = 18; weight 25-35 kg) were divided into three groups: I, control group (n = 6), Ringer's lactate only; II, haemodialysate group (n = 6), Ringer's lactate and a protein-free haemodialysate of calf-blood (ACTIHAEMYL20%; AH) and III, C1-inhibitor group (n = 6), Ringer's lactate and C1-inhibitor (C1-INH; BERINERT). Skin biopsies were taken at defined time points (4, 28, 52 and 76 h) and investigated histologically. Depth of burn was determined morphometrically after coloration with a modified MTT-staining on frozen sections o…

medicine.medical_specialtySwineComplement C1 Inactivator ProteinsCritical Care and Intensive Care MedicineStatistics NonparametricMicrocirculationC1-inhibitorRandom AllocationReference ValuesBiopsySkin surfacemedicineScaldingAnimalsSkinWound Healingmedicine.diagnostic_testbiologybusiness.industryBiopsy NeedleHistologyGeneral Medicinemedicine.diseaseSurgeryDisease Models AnimalProtein freeAnesthesiaDisease ProgressionEmergency Medicinebiology.proteinActihaemylSurgeryBurnsWound healingbusinessComplement C1 Inhibitor ProteinBurns
researchProduct

The challenge of the volume status assessment in heart failure.

2009

medicine.medical_specialtySystoleBlood volumeDoppler echocardiographyVentricular Dysfunction LeftInternal medicinemedicineIntravascular volume statusVentricular PressureHumansSystoleHeart FailureBlood Volumemedicine.diagnostic_testbusiness.industryDisease progressionmedicine.diseasePrognosisEchocardiography DopplerHeart failureCardiologyVentricular pressureheart failure volume status assessmentDisease ProgressionCardiology and Cardiovascular MedicinebusinessAmerican heart journal
researchProduct

Predictors of Progression in Hypertensive Renal Disease in Children

2004

In hypertensive renal disease in children, several risk factors influence the development and the rate of progression of renal damage, including blood pressure levels, proteinuria, lipid disorders, and genetic differences. The impact of blood pressure on renal structures, the most important of the factors, depends not only on blood pressure levels, but also on the persistence of the blood pressure levels over time, mainly during the hours when the patient is resting or sleeping. Abnormal circadian variability is frequently observed in patients with renal damage, and nocturnal blood pressure reduction should be a major therapeutic objective to protect against a decline in renal function. Pro…

medicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismRenal functionDiseaseurologic and male genital diseasesRisk FactorsInternal medicineInternal MedicineHumansMedicineIn patientCircadian rhythmChildReview PaperProteinuriabusiness.industryRenal damageAge FactorsPrognosisNocturnal blood pressureProteinuriaBlood pressureEndocrinologyHypertensionDisease ProgressionCardiologyKidney Diseasesmedicine.symptomCardiology and Cardiovascular MedicinebusinessThe Journal of Clinical Hypertension
researchProduct

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Glob…

2016

Abstract Introduction: Panobinostat (PAN) is a potent pan-deacetylase inhibitor that targets multiple myeloma (MM) cells via its epigenetic effects as well as its effect on the aggresome. In the PANORAMA 1 phase 3 trial, the combination of PAN, bortezomib (BTZ), and dexamethasone (Dex; PAN+BTZ+Dex) significantly increased progression-free survival compared with placebo plus BTZ and Dex, leading to approval in Europe of the combination for the treatment of patients with MM who have received ≥ 2 prior regimens, including BTZ and an immunomodulatory agent. The purpose of this expanded treatment protocol (ETP) is to further evaluate safety and to provide panobinostat prior to commercial availab…

medicine.medical_specialtyTreatment protocolBortezomibbusiness.industryImmunologyDisease progressionCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryOlder populationSurgerychemistry.chemical_compoundchemistryTolerabilityInternal medicinePanobinostatmedicinebusinessDexamethasonemedicine.drugBlood
researchProduct

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

2012

Item does not contain fulltext CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findi…

medicine.medical_specialtyUrologymedicine.medical_treatmentUrologyMEDLINEAntineoplastic AgentsContext (language use)Aetiology screening and detection [ONCOL 5]CystectomyQuality of Care [ONCOL 4]Molecular epidemiology [NCEBP 1]CystectomyTranslational research [ONCOL 3]medicineHumansNeoplasm InvasivenessProspective cohort studyNeoplasm StagingBladder cancermedicine.diagnostic_testbusiness.industryGeneral surgeryCarcinoma in situCystoscopymedicine.diseaseAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsBCG VaccineDisease ProgressionNeoplasm GradingNeoplasm Recurrence LocalUrotheliumbusinessIntravesical chemotherapyCarcinoma in SituEuropean Urology
researchProduct

Substance P is upregulated in the serum of patients with chronic spontaneous urticaria.

2014

medicine.medical_specialtyUrticariaMEDLINESubstance PDermatologyAnxietySubstance PBiochemistrySeverity of Illness Indexchemistry.chemical_compoundText miningQuality of lifeDownregulation and upregulationInternal medicineGermanySeverity of illnessMedicineHumansMolecular Biologybusiness.industryDepressionDisease progressionCell BiologyUp-RegulationMulticenter studychemistryChronic DiseaseDisease ProgressionQuality of LifebusinessBiomarkersThe Journal of investigative dermatology
researchProduct

Disease Progression in COPD Patients Classified as Gold D According to Gold 2011 or Gold 2017 in the Real-Life Daccord Study

2019

medicine.medical_specialtybusiness.industryCopd patientsInternal medicineDisease progressionMedicinebusinessC102. COPD: RISK PREDICTION AND PROGNOSIS
researchProduct

Progressively fading asymptomatic brownish macules

2010

medicine.medical_specialtybusiness.industryDermatologyDermatologyAsymptomaticHyperpigmentationDisease ProgressionmedicineHumansFemaleFadingmedicine.symptomChildbusinessFollow-Up StudiesClinical and Experimental Dermatology
researchProduct